You have accessJournal of UrologyProstate Cancer: Detection and Screening I1 Apr 2015MP48-02 FLUORESCENCE SPECTROSCOPY CAN INCREASE DIAGNOSTIC YIELD OF PROSTATE BIOPSIES E. David Crawford, Edward A. Jasion, Yongjun Liu, John Daily, Paul Arangua, Clifford Jones, S. Russell Nash, and Priya Werahera E. David CrawfordE. David Crawford More articles by this author , Edward A. JasionEdward A. Jasion More articles by this author , Yongjun LiuYongjun Liu More articles by this author , John DailyJohn Daily More articles by this author , Paul AranguaPaul Arangua More articles by this author , Clifford JonesClifford Jones More articles by this author , S. Russell NashS. Russell Nash More articles by this author , and Priya WeraheraPriya Werahera More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.1676AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Transrectal ultrasound (TRUS) guided prostate biopsy cores have a very low diagnostic yield as 90% cores are histopathologically classified as benign. We investigated potential clinical application fluorescence spectroscopy (FS) to increase diagnostic yield of TRUS biopsies. The fluorescence emissions from natural fluorophores (e.g., collagen) in prostate tissue are altered by the presence of prostate cancer (PCa). Thus, FS can be used to distinct malignant locations from benign to aid TRUS biopsies. METHODS 14G optical biopsy needle was prototyped to capture FS of prostate tissue. Integrated optical sensor uses 8x100 μm fibers for excitation and 1x200 μm fiber to collect FS data. Custom made fluorometers with 2 light-emitting diodes at 290 and 340 nm and a spectrometer were used to measure FS of prostate tissue. User interface for fluorometer operation and data collection was developed using LabView software. Each spectral data acquisition takes ∼250 milliseconds. The in vivo biopsies were performed during radical prostatectomy surgery on the exposed prostate with blood flow to the gland intact. A tissue biopsy core was obtained from each biopsy site after acquisition of FS data. Above procedure was repeated ex vivo after surgical excision of the prostate. Biopsy cores were histopathologically classified as benign or malignant and correlated with corresponding FS data. Partial Least Square analysis of the FS data was performed to determine principal components (PCs) at each excitation wavelength. Using linear support vector machine and leave-one-out cross validation method, several combinations of PCs were tested for their ability to classify benign vs. malignant prostatic tissue. RESULTS Thirteen patients were consented. A total of 208 in vivo biopsies (29 malignant) and 224 ex vivo biopsies (51 malignant) were analyzed. Results for benign vs. malignant prostatic tissue classification based on number of PCs used are given in the table. CONCLUSIONS Our optical biopsy needle assisted with FS has a very high NPV to indicate benign tissue while sufficient SE and SP for real-time diagnosis of PCa by targeting areas positive for cancer within the prostate gland. Hence, systematic use of optical biopsies can potentially increase diagnostic yield of prostate biopsies. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e594 Peer Review Report Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information E. David Crawford More articles by this author Edward A. Jasion More articles by this author Yongjun Liu More articles by this author John Daily More articles by this author Paul Arangua More articles by this author Clifford Jones More articles by this author S. Russell Nash More articles by this author Priya Werahera More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...